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Abstract
Background
Many patients with cancer or other systemic illnesses can experience malnutrition. One way
to mitigate malnutrition is by insertion of a percutaneous endoscopic gastrostomy feeding
tube (PEG tube). The goal of this retrospective matched cohort study is to evaluate if PEG
tube placement improved nutritional status and overall survival (OS) in advanced gastro-
esophageal (GE) cancer patients who are undergoing anti-neoplastic therapy.
Methods
GE cancer patients who were treated and evaluated by a nutritionist and had at least 2 nutri-
tionist follow-up visits were identified. Patients with PEG tube were matched to patients that
did not undergo PEG placement (non-PEG). Clinical characteristics, GE symptoms reported
at nutrition follow-up visits, and OS were recorded.
Results
20 PEG and 18 non-PEG cases met criteria for further analyses. After correction for multiple
testing, there were no OS differences between PEG and non-PEG, treatment naive and pre-
viously treated. However, PEG esophageal carcinoma has statistically significant inferior
OS compared with non-PEG esophageal carcinoma. PEG placement did not significantly
reduce the proportion of patients with weight loss between the initial nutrition assessment
and 12-week follow-up.
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Conclusions
In this small study, PEG placement had inferior OS outcome for GE esophageal carcinoma,
no improvement in OS for other evaluated groups, and did not reduce weight loss between
baseline and 12-week follow-up. Unless there is prospective randomized trial that can show
superiority of PEG placement in this population, PEG placement in this group cannot be
endorsed.
Introduction
Gastroesophageal (GE) cancers are known to commonly produce a variety of GE-related
symptoms, such as dysphagia and cachexia that can lead to malnutrition [1]. The prevalence of
malnutrition incidents in these populations can range from 40–85% of patients [1,2]. Control-
ling malnutrition is a major concern in the treatment of patients undergoing anti-neoplastic
therapy. Cancer-associated malnutrition has been shown to lower a patient’s response to anti-
neoplastic therapies, as well as, amplify the risk of chemotherapy-induced toxicity [3]. In addi-
tion, malnutrition is one of the main contributors towards a decline in a patient’s nutritional
status and their overall quality of life (QoL) [4]. Malnutrition has also been shown to lead to an
increase in health care costs [5]. Thus, mitigating and alleviating malnutrition is a major con-
cern in the management of cancer patients receiving anti-neoplastic therapies.
One way to remedy malnutrition is through the use of a percutaneous endoscopic gastro-
stomy feeding tube (PEG tube). PEG tubes are inserted into the stomach, usually through
abdominal wall, and are used to provide enteral nutrition to patients in which the oral cavity
must be bypassed [6]. While previous studies have shown a a positive correlation between
nutritional stasis and overall QoL, the relationship between PEG tube use, nutrition status, and
treatment outcomes in patients who are undergoing anti-neoplastic therapies has not been
thoroughly examined [7–10].
The goal of this retrospective matched cohort study is to evaluate if PEG tube placement
improved nutritional status and overall survival (OS) in advanced GE cancer patients who are
undergoing anti-neoplastic therapy.
Materials and methods
Ethics statement
The study was conducted based on the ethical standards prescribed by the Helsinki Declara-
tion of the World Medical Association and with the approval of the Western Institutional
Review Board (WIRB) study #20140710. As this was a retrospective study of existing data, the
requirement for patient consent was waived by WIRB and consent was not obtained for this
study. Clinical information was collected, and patients were de-identified by removing all
identifiers that could be linked back to the patient.
Study design
We identified GE cancer patients with metastatic disease that received oncology care at a single
comprehensive cancer center and were evaluated by a nutritionist, between December 2008
to February 2014 and had at least 2 nutritionist follow-up visits. The first follow-up visit was
between 4–6 weeks and the second visit was approximately at 12 weeks from the initial nutri-
tion assessment. Patients with PEG tube were matched by histology type, similar age range
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(+/- 5 years), treated during a similar time frame (within ~12 months of each other) to patients
that did not undergo PEG placement (non-PEG).
Study endpoints
Statistical analysis. Age, gender tumor histology, stage at initial assessment at the cancer
center, weight change, and the symptoms nausea, diarrhea, constipation, taste changes, sensi-
tivity to smells, dysphagia, odynophagia, anorexia, cachexia, edema, and anemia were mea-
sured at baseline, once between 4–6 weeks and then at 12 weeks from the baseline assessment.
Type of prior therapy and OS from time of initial nutritionist consultation were recorded as
well. To determine the nutritional status of the patients, the weight loss percentages of patients
over the course of 12 weeks were recorded and chi square statistics were calculated to deter-
mine if the findings were statistically significant. For OS, Kaplan-Meier survival curves were
constructed under specific perimeters. Two-tailed p-values less than 0.05 were considered sta-
tistically significant. For multiple tests evaluating OS, Bonferroni correction was applied and a
p-value less than 0.010 was considered statistically significant.
Results
Patient characteristics
Initially there were 27 GE patients identified with PEG tube placement, and another 21 GE
patients that did not have PEG tube placement during this time frame that were available for
cohort matching (non-PEG). Upon further review of records, 10 patients, seven PEG and 3
non-PEG, were considered not evaluable due to insufficient follow-up (Fig 1 and S1 Table).
Of those patients with PEG tube placement, 16 had adenocarcinoma histology, 9 had squa-
mous cell carcinoma (SCC), and 2 had neuroendocrine tumors. Of those non-PEG patients
identified, 11 had adenocarcinoma histology, 9 had SCC, and 1 had neuroendocrine histology
(Table 1). PEG patients were significantly less likely to be treatment-naive (p = 0.019) and had
a higher prevalence of esophageal cancer (p = 0.023).
Tables 2 and 3 depict the symptoms of PEG and non-PEG patients recorded at baseline
and the follow-up nutritional assessments, respectively. The PEG tube population reported
a decrease in anorexia and nausea but an increase in dysguesia between baseline and the
Fig 1. CONSORT diagram. CONSORT diagram depicting number of patients evaluated for eligibility and number of patients included in analysis.
https://doi.org/10.1371/journal.pone.0188628.g001
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12-week nutritional assessment. The non-PEG tube population reported lower decreased
appetite, dysphagia, and cachexia during this interval.
Fig 2 shows the OS between patients receiving PEG tube placement and the matched non-
PEG cohort (p = 0.0323), after correction for multiple testing this did not reach statistical
significance.
Fig 3 shows the OS differences between PEG adenocarcinoma patients and the matched
non-PEG adenocarcinoma cohort (p = 0.0309), after correction for multiple testing this did
not reach statistical significance.
The survival difference is significantly more pronounced between PEG tube and non-PEG
esophageal carcinoma patients (p = 0.0090), favoring non-PEG (Fig 4).
In contrast to adenocarcinoma, for SCC there is no OS difference between PEG tube and
non-PEG tube patients (p = 0.8181) (S1 Fig).
Receipt of prior systemic therapy does not appear to influence OS in patients (p = 0.6179)
(S2 Fig).
PEG placement did not significantly reduce the proportion of patients with weight loss
between the initial nutrition assessment and 12-week follow-up (S2 and S3 Tables). For the
overall population, there was a non-statistically significant increase in the proportion of
patients with< 4.9% weight loss by the 12-week follow-up (S4 Table).
Table 1. Clinical characteristics.
Clinical Characteristics PEG n = 20 Non-PEG n = 18
Median age (range) 58 (30–66) 55 (35–63)
Gender Male 19/ Female 1 Male 17/ Female 1
Esophageal cancer 16 8
Gastroesophageal junction cancer 4 10
Percentage weight loss at baseline nutrition assessment >4.9%: 11, <5.0%: 9 >4.9%: 10, <5.0%: 8
Treatment-naive prior to nutrition assessment 26.7% (n = 15) 68.8%(n = 16)
https://doi.org/10.1371/journal.pone.0188628.t001
Table 2. Symptoms of PEG patients (n = 20).
Nausea Diarrhea Constipation Dysguesia Decreased
appetite
Dysphagia Odynophagia Edema Anorexia Cachexia Anemia
Baseline
(%)
9 (45) 5 (25) 5 (25) 3 (15) 8 (40) 13 (65) 3 (15) 2 (10) 7 (35) 2 (10) 4 (20)
4–6 Weeks
(%)
10 (50) 4 (20) 3 (15) 5 (25) 5 (25) 13 (65) 6 (30) 3 (15) 2 (10) 2 (10) 2 (10)
12 Weeks
(%)
10 (50) 4 (20) 4 (20) 6 (30) 6 (30) 10 (50) 4 (20) 1 (5) 3 (0.15) 1 (5) 1 (5)
https://doi.org/10.1371/journal.pone.0188628.t002
Table 3. Symptoms of non-PEG patients (n = 18).
Nausea Diarrhea Constipation Dysguesia Decreased
Appetite
Dysphagia Odynophagia Edema Anorexia Cachexia Anemia
Baseline
(%)
2 (11) 2 (11) 3 (17) 2 (11) 7 (39) 8 (44) 2 (11) 0 2 (11) 3 (17) 1 (6)
4–6 Weeks
(%)
3 (17) 1 (6) 1 (6) 2 (11) 3 (17) 7 (39) 2 (11) 0 1 (6) 1 (6) 0
12 Weeks
(%)
2 (11) 4 (22) 1 (6) 2 (11) 4 (22) 4 (22) 1 (6) 1 (6) 1 (6) 0 0
https://doi.org/10.1371/journal.pone.0188628.t003
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Discussion
The OS for patients with metastatic GE cancers is poor. The prognosis is worse for those
experiencing GE-related symptoms, especially malnutrition. The cause of the malnutrition is
primarily due to the cancer and overall tumor burden. If a systemic therapy is appropriate and
successful in significantly decreasing tumor burden, patients can experience an improvement
in QoL, including nutrition status [8]. The ability to mitigate malnutrition by proactive mea-
sures in an effort to optimize the patient to receive systemic therapy are sought. Several options
exist including nutrition counseling and interventions such as PEG tube placement. The rela-
tionship between PEG tube placement, nutrition status, and OS outcomes in metastatic GE
cancer patients undergoing systemic therapy has not been well-examined.
Fig 2. OS comparing PEG vs non-PEG in all patients. Kaplan-Meier curve depicting the estimated OS of all patients. The line with circles depicts PEG
patients, while the line with squares depicts non-PEG patients. P-value is not significant after Bonferroni correction.
https://doi.org/10.1371/journal.pone.0188628.g002
Fig 3. OS comparing PEG vs non-PEG in adenocarcinoma. Kaplan-Meier curve depicting the estimated OS for patients with adenocarcinoma. The
line with circles depicts PEG adenocarcinoma patients, while the line with squares depicts non-PEG adenocarcinoma patients. P-value is not significant
after Bonferroni correction.
https://doi.org/10.1371/journal.pone.0188628.g003
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The main finding from our retrospective case matched analysis is that the OS for PEG tube
esophageal carcinoma population was significantly worse than the non-PEG esophageal carci-
noma population (Fig 4). This result was surprising. As clinicians, we believe that for those
patients unable to maintain adequate nutrition, that it would be logical that this intervention
would help sustain and nutritionally optimize a patient to receive and continue with systemic
therapy. Due to the small numbers in this retrospective analysis and multiple testing, we were
not able to show overall that PEG compared with non-PEG had statistically different OS.
There did not appear to be a difference in OS in SCC patients or those who received prior sys-
temic therapy at the time of initial nutrition assessment.
The non-PEG tube population reported lower decreased appetite, dysphagia, and cachexia
at the 12-week assessment compared to the initial nutrition assessment. The PEG tube popula-
tion reported a decrease in anorexia and nausea but an increase in dysguesia during this inter-
val. Overall, both PEG and non-PEG populations did not have any statistically significant
weight loss changes at the 12-week nutrition assessment.
There are a few limitations associated with this study. The study was retrospective and the
sample size was small. Retrospective studies have recorded limitations themselves such as diffi-
culty in determining a cause and effect relationship, as well as, relying on past recordings of
data [1]. Small sample sizes often cause outlier data to more profound, which can skew the
overall results. Even though this study was limited to GE cancers, systemic treatments vary
somewhat and evaluation of patients were not uniform in their disease spectrum. Some
patients were treatment naïve while others had prior systemic therapy elsewhere before being
evaluated at the cancer center. Overall, the two groups were well matched. The PEG group did
have a significantly higher proportion of patients with esophageal cancer and patients that had
prior treatment before the baseline nutritionist evaluation, which could impact OS. However,
S2 Fig, shows similar OS curves between treatment-naive and previously treated patients.
Despite these limiting factors, we still observed a significant difference in OS in GE esophageal
carcinoma patients favoring non-PEG after Bonferroni correction. We also acknowledge that
this study has some limitations with regards power, selection bias, design, and indication bias,
however, the current realities of clinical practice impede a prospective randomized trial from
Fig 4. OS comparing PEG vs non-PEG in esophageal carcinoma. Kaplan-Meier curve depicting the estimated OS for patients with esophageal
carcinoma. The line with circles depicts PEG esophageal carcinoma patients, while the line with squares depicts non-PEG esophageal carcinoma
patients. P-value is significant after Bonferroni correction.
https://doi.org/10.1371/journal.pone.0188628.g004
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being carried out practically without some supporting information to justify the time, expense,
and effort. We hope that our findings will foster sufficient interest to attempt to prove or dis-
prove the benefit of PEG in cancer patients. Unless there is prospective randomized trial that
can demonstrate superiority of PEG placement in this population, PEG placement in this
group cannot be endorsed.
Supporting information
S1 Fig. OS comparing PEG vs non-PEG in SCC. Kaplan-Meier curve depicting the estimated
OS for SCC patients. The line with circles depicts PEG SCC patients, while the line with
squares depicts non-PEG SCC patients. P-value is not significant after Bonferroni correction.
(TIF)
S2 Fig. OS difference between systemic therapy naive vs previously treated patients prior
to initial nutrition assessment. Kaplan-Meier curve depicting the estimated OS for patients
with and without prior systemic therapy at the time of initial nutrition assessment. The line
with circles depicts patients that received prior systemic therapy at the time of initial nutrition
assessment, while the line with squares depicts systemic therapy naïve patients at the time of
initial nutrition assessment. P-value is not significant after Bonferroni correction.
(TIF)
S1 Table. De-identified dataset. This is the dataset for all 48 identified patients.
(XLSX)
S2 Table. Comparison of PEG vs. non-PEG patients with less than 4.9% weight loss
between initial nutrition assessment and 12-week follow-up. Number of cases of PEG vs.
non-PEG with less than 4.9% weight loss between these time points.
(DOCX)
S3 Table. Comparison of PEG vs. non-PEG patients with greater than 5% weight loss
between initial nutrition assessment and 12-week follow-up. Number of cases of PEG vs.
non-PEG with more than 5% weight loss between these time points.
(DOCX)
S4 Table. Comparison of weight loss changes by less than 4.9% vs greater than 5% between
initial nutrition assessment and 12-week follow-up. Number of cases of with weight loss less
than 4.9% vs. weight loss more than 5% between these time points.
(DOCX)
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